Evidence map›Paper›PMID 42653360›Full record

ArticleInternational journal of molecular sciences2026

Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

Katja Seipel, Marta Gonçalves Fonseca, Inna Shaforostova, Seok-Yun Lee, Ulrike Bacher, Thomas Pabst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katja SeipelDepartment for Biomedical Research, University of Bern, 3008 Bern, Switzerland.ORCID 0000-0003-3128-1573
Marta Gonçalves FonsecaDepartment of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
Inna ShaforostovaDepartment of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
Seok-Yun LeeDepartment of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.ORCID 0000-0002-1349-4922
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.ORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor CAR T-cells are effective immunotherapies for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with overall response rates of 63-84% and complete response rates of 43-54%. Programmed cell death protein 1 (PD-1) is a cell surface receptor with immune check-point function. There are several common germline variants of the

Indexed as

Germ-Line MutationImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseProgrammed Cell Death 1 ReceptorAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesTreatment OutcomePDCD1 protein, humanProgrammed Cell Death 1 Receptoractivating enhancer binding protein 4 (AP4)B-lymphocyte antigen CD19CAR-T cell therapydiffuse large B-cell lymphoma (DLBCL)FMC63-chimeric antigen receptor (FMC63-CAR)minor allele frequency (MAF)myeloid zinc-finger 1 (MZF1)programmed cell death protein 1 (PD-1)single nucleotide polymorphism (SNP)

Identifiers

PMID42653360
PMCPMC13513131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.